Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome.
OBJECTIVE
To report the result of ranibizumab administration in an eye with ocular ischaemic syndrome.


METHODS
Fluorescein angiography, ocular pneumoplethysmography and retinal vessel calibre measurement.


RESULTS
An 85-year-old man with ocular ischaemic syndrome demonstrated vision loss, retinal vessel calibre constriction and profound retinal ischaemia after intravitreal ranibizumab.


CONCLUSIONS
We advise against the use of intravitreal vascular endothelial growth factor inhibitors in eyes with ocular ischaemic syndrome.
Kofoed
Peter Kristian
PK
Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark. peter.k@dadlnet.dk
Munch
Inger Christine
IC
Larsen
Michael
M
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000075202:Contraindications; D005123:Eye / Q000098:blood supply* / Q000000981:diagnostic imaging; D005451:Fluorescein Angiography; D006801:Humans; D056965:Injections, Intraocular; D007511:Ischemia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010991:Plethysmography / Q000379:methods; D011859:Radiography; D000069579:Ranibizumab; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology; D013577:Syndrome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014661:Vasoconstriction; D014786:Vision Disorders / Q000209:etiology; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab